BioSpace News Archive

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products.

Verona Pharma plc announces its development partner, Nuance Pharma, has received clearance from the Center of Drug Evaluation for its Investigational New Drug application to conduct both Phase 1 and Phase 3 studies with ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease in mainland China.

At Medivir’s AGM on May 5, Uli Hacksell, Lennart Hansson, Bengt Westermark and Yilmaz Mahshid were re-elected and Anette Lindqvist was newly elected as board members in the company. Uli Hacksell was re-elected as chairman of the board. An van Es Johansson had declined re-election.

Skanska and the Kronoberg Region have signed an agreement on phase one of the work on Växjö’s new emergency hospital.

J INTS BIO announced that it held its 1st International Advisory Board Meeting for its Novel Oral 4th Generation EGFR-TKI ‘JIN-A02' on the sideline of the 2022 IASLC World Conference on Lung Cancer held in Vienna, Austria, on 7th August.

The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, announced that EMA has validated the Marketing Authorization Application for elacestrant, a selective estrogen receptor degrader, for patients with ER+/HER2- advanced or metastatic breast cancer.

IMPACT Therapeutics announced that the US Food and Drug Administration has granted Orphan-Drug Designation to our fixed-dose combination capsule of Senaparib and temozolomide for the treatment of adult patients with small cell lung cancer.

Immuron Limited announced that it has deprioritized SARS-CoV-2 research to focus on the clinical development of our more advanced stage therapeutic drug candidates.

SpringWorks Therapeutics, Inc. announced that data from the Phase 3 DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, will be presented as a late-breaking oral presentation at the European Society for Medical Oncology Congress 2022.

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce it has secured a promising new customer in the Mexican dairy industry.